The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

The move is expected to cause a “near-term stock out of Bicillin L-A,” Pfizer said in its statement, with the drugmaker now ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

As advances in artificial intelligence technology continue to offer enticing benefits to industries across the board, pharma ...

Back in May, Bain and Botanic spent $26 million to acquire the property from Fujifilm Recording Media. The 15-acre site will ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

ZoomRx surveyed 57 neurologists in the U.S. this month, revealing that no single drug brand holds more than 5% of top-of-mind ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...